Mean change in PROMIS29+MSx (±SD) by diagnosis
| Domain (MIC) | RA (n=41) | LC (n=30) | PsA (n=22) | PsO (n=18) | SLE (n=13) | IBD (n=12) | MS (n=12) | AS (n=11) | Other AIDs (n=30) | No AID (n=19) |
| Soc roles (3.7) | 6.9 (7.9) | 5.1 (7.1) | 6.1 (6.9) | 5.0 (7.0) | 6.6 (7.5) | 1.7 (4.7) | 1.8 (4.9) | 9.9 (4.8) | 6.7 (8.3) | 3.3 (7.5) |
| Cog func (3.9) | 2.8 (5.8) | 4.4 (7.1) | 2.0 (5.6) | 4.1 (7.4) | 5.7 (6.2) | −0.8 (8.6) | 5.8 (9.6) | 4.5 (7.6) | 2.2 (8.5) | 1.5 (10.5) |
| Man sx (4.0) | 8.7 (9.0) | 6.7 (6.6) | 5.1 (7.3) | 4.3 (8.5) | 3.3 (8.2) | 7.0 (9.1) | 8.0 (6.1) | 5.2 (7.8) | 5.6 (7.1) | 7.2 (7.9) |
| Phys func (3.2) | 3.3 (6.4) | 5.6 (5.1) | 4.0 (7.1) | 1.0 (6.3) | 3.5 (7.7) | 3.5 (4.7) | −0.9 (5.2) | 2.6 (5.9) | 4.1 (7.7) | 0.5 (5.2) |
| Anx (−3.7) | −4.1 (6.7) | −5.6 (7.3) | −4.9 (7.3) | −3.7 (7.3) | −4.8 (7.6) | −1.6 (5.7) | −0.7 (7.3) | −6.6 (8.7) | −4.8 (7.4) | −5.1 (8.2) |
| Depres (−3.3) | −3.5 (6.3) | −4.7 (6.1) | −2.1 (6.8) | −1.6 (6.8) | −4.1 (7.9) | −2.8 (6.0) | −3.1 (7.3) | −4.9 (5.7) | −2.1 (7.1) | −4.2 (5.8) |
| Fatigue (−4.9) | −7.8 (11.1) | −9.0 (9.4) | −8.2 (11.7) | −7.1 (10.9) | −11.8 (7.1) | −3.2 (8.3) | −6.9 (5.8) | −7.3 (7.7) | −7.8 (9.7) | −10.1 (9.2) |
| P interf (−4.2) | −7.1 (9.1) | −5.1 (10.0) | −6.6 (7.9) | −4.6 (9.5) | −4.1 (6.1) | −5.6 (6.3) | −3.6 (9.4) | −5.7 (3.7) | −6.4 (7.8) | −4.9 (8.3) |
| Sleep (−3.8) | −7.0 (6.8) | −6.0 (7.0) | −6.4 (8.7) | −7.1 (8.4) | −6.8 (8.2) | −2.0 (7.8) | −6.8 (4.0) | −6.6 (7.9) | −3.9 (8.1) | −5.0 (6.0) |
| P intens (−1.1) | −1.9 (2.3) | −1.0 (2.6) | −2.1 (2.5) | −1.0 (2.1) | −2.5 (2.3) | −1.8 (1.5) | −1.4 (2.1) | −0.8 (2.0) | −1.0 (1.8) | −1.4 (1.8) |
Values in black bold text were statistically significant; values in italicised text were not statistically significant.
MIC was established by domain using descriptive statistics (mean and SD in T-scores) to define thresholds 0.5 SDs from the mean.
AID, autoimmune disease; Anx, anxiety; AS, ankylosing spondylitis; Depres, depression; Cog func, cognitive function; IBD, inflammatory bowel disease; LC, long COVID; Man sx, ability to manage symptoms; MIC, minimal important change; MS, multiple sclerosis; Phys func, physical function; P intens, pain intensity; P interf, pain interference; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; Sleep, sleep disturbance; Soc roles, ability to participate in social roles and activities.